Posted by Michael Wonder on 17 Nov 2022
Ruxolitinib phosphate for the treatment of patients with chronic graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for the treatment of patients 12 years of age and older with chronic graft versus host disease that is refractory to the use of corticosteroids.
This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
